Study of Compound Shelong Capsules on inhibiting Bax/Caspase-3 signaling pathway and reducing apoptosis in renal tissues of rats with membranous nephropathy
JIA Shiyan1 ZHONG Qiming2 SI Ruihua1 FAN Xiaoyang2 YAN Wenyun1 LIU Guangzhen2
1.Shanxi University of Chinese Medicine, Shanxi Province, Jinzhong 030619, China;
2.Shanxi Institute of Traditional Chinese Medicine, Shanxi Province, Taiyuan 030012, China
Abstract：Objective To investigat the effect of Compound Shelong Capsules on inhibiting Bax/Caspase-3 signaling pathway and reducing apoptosis in renal tissues of rats with membranous nephropathy. Methods Ten SPF male SD rats aged six weeks were selected as normal group, and the other 40 rats were injected with cationic bovine serum albumin (Alb) to construct the rat model of membranous nephropathy. They were divided into model group, Tripterygium Wilfordii Polyglycoside Tablets group, Compound Shelong Capsules low-dose and high-dose groups, with 10 rats in each group by random number table method. Except normal group and model group were given the same amount of normal saline, other groups were given the corresponding drug intragastric administration for four weeks. HE staining, Masson staining, transmission electron microscopy, and scanning electron microscopy were used to observe the pathological changes of renal tissues in each group; the contents of urinary microalbumin (mAlb), serum creatinine (SCr), triglyceride (TG), total cholesterol (TC), Alb, and total protein (TP) were compared among all groups; the apoptosis rate of renal tissues cells in each group was compared; the expression levels of Nephrin, Podocin, Bcl-2, Bax, and Caspase-3 mRNA in renal tissues of all groups were compared. Results Compared with normal group, the content of urinary mAlb in model group was increased (P＜0.05); the contents of serum Alb and TP were decreased, while the contents of TC, TG, and SCr were increased (P＜0.05). Compared with model group, the contents of urinary mAlb in Compound Shelong Capsules low-dose and high-dose groups was decreased (P＜0.05); the contents of serum Alb and TP were increased, while the contents of TC, TG, and SCr were decreased (P＜0.05). Compared with Compound Shelong Capsules low-dose group, the content of urinary mAlb in Compound Shelong Capsules high-dose group was decreased (P＜0.05); the contents of serum Alb and TP were increased, while SCr was decreased (P＜0.05). In the normal group, the structure of glomeruli was intact by HE staining; but no tissue fibrosis was observed by Masson staining. In model group, HE staining showed increased glomerular volume and vacuolar degeneration of renal tubules, accompanied by protein tubule type; Masson staining showed tissue fibrosis and blue collagen fiber tissue. Compared with model group, glomerular volume increased, tubular vacuolar degeneration and tissue fibrosis decreased in Compound Shelong Capsules low-dose and high-dose groups. In normal group, the structure of basement membrane was intact, and the structure of podocytes was normal; in model group, the glomerulus was edema, the basement membrane thickened, the foot process fused and widened, the structure of podocytes was seriously damaged, and cytoskeletal proteins were exposed; compared with model group, basilar membrane thickening was reduced and podocyte morphology and structure tended to be normal in Compound Shelong Capsules low-dose and high-dose groups. Compared with normal group, the apoptosis rate of renal tissues cells in model group was increased (P＜0.05); compared with model group, the apoptosis rate of renal tissues cells in Compound Shelong Capsules low-dose and high-dose groups was decreased (P＜0.05); compared with Compound Shelong Capsules low-dose group, the apoptosis rate of renal tissues in Compound Shelong Capsules high-dose group was decreased (P＜0.05). Compared with normal group, the expression levels of Nephrin, Podocin, and Bcl-2 mRNA in model group were decreased, the expression levels of Caspase-3 and Bax mRNA were increased, and Bcl-2/Bax ratio was decreased (P＜0.05). Compared with model group, the expression levels of Nephrin, Podocin, and Bcl-2 mRNA in Compound Shelong Capsules low-dose and high-dose groups were increased, the expression levels of Caspase-3 and Bax mRNA were decreased, and Bcl-2/Bax ratio was increased (P＜0.05). Compared with Compound Shelong Capsules low-dose group, the expression levels of Nephrin and Podocin mRNA in Compound Shelong Capsules high-dose group were increased, while Bcl-2/Bax ratio was increased (P＜0.05). Conclusion Compound Shelong Capsules can effectively improve albuminuria in rats with membranous nephropathy, significantly reduce renal pathological injury, and delay the progression of membranous nephropathy, the mechanism of which may be related to the inhibition of podocyte apoptosis.
贾世艳1 仲启明2 司瑞花1 范晓阳2 严文允1 刘光珍2. 复方蛇龙胶囊抑制Bax/Caspase-3信号通路减轻膜性肾病大鼠肾组织细胞凋亡的研究[J]. 中国医药导报, 2023, 20(1): 13-18,28.
JIA Shiyan1 ZHONG Qiming2 SI Ruihua1 FAN Xiaoyang2 YAN Wenyun1 LIU Guangzhen2. Study of Compound Shelong Capsules on inhibiting Bax/Caspase-3 signaling pathway and reducing apoptosis in renal tissues of rats with membranous nephropathy. 中国医药导报, 2023, 20(1): 13-18,28.
[1] Hamilton P，Wilson F，Chinnadurai R，et al. The investigative burden of membranous nephropathy in the UK [J]. Clin Kidney J，2020，13（1）：27-34.
[2] Cattran DC，Brenchley PE. Membranous nephropathy：integrating basic science into improved clinical management [J]. Kidney Int，2017，91（3）：566-574.
[3] Tang L，Yao J，Kong X，et al. Increasing prevalence of membranous nephropathy in patients with primary glomerular diseases：A cross-sectional study in China [J]. Nephrology（Carlton），2017，22（2）：168-173.
[4] Bomback AS，Fervenza FC. Membranous Nephropathy：Approaches to Treatment [J]. Am J Nephrol，2018，47 Suppl 1：30-42.
[5] 左俊荣.特发性膜性肾病的诊断及治疗研究[J].医学信息，2021，34（11）：54-56.
[6] Liu B，Lu R，Li H，et al. Zhen-wu-tang ameliorates membranous nephropathy rats through inhibiting NF-κB pathway and NLRP3 inflammasome [J]. Phytomedicine，2019， 59：152913.
[7] Jin LW，Pan M，Ye HY，et al. Down-regulation of the long non-coding RNA XIST ameliorates podocyte apoptosis in membranous nephropathy via the miR-217-TLR4 pathway [J]. Exp Physiol，2019，104（2）：220-230.
[8] Lang R，Wang X，Liang Y，et al. Research Progress in the Treatment of Idiopathic Membranous Nephropathy using Traditional Chinese Medicine [J]. J Transl Int Med，2020，8（1）：3-8.
[9] 高飞，王泽泽，杨冰，等.加味升降散对膜性肾病大鼠Notch信号通路及足细胞凋亡的影响[J].中国实验方剂学杂志，2021，27（4）：30-36.
[10] 张李博，吴金鸿，王瑶，等.刘光珍教授应用分消走泄法治疗慢性肾脏病经验[J]. 四川中医，2021，39（4）：9-11.
[11] 张越，刘光珍.刘光珍教授从“邪实为本”论治慢性肾脏病[J].中国中西医结合肾病杂志，2020，21（3）：249-251.
[12] 闫梦苗，刘光珍.复方蛇龙胶囊的拆方研究[J].时珍国医国药，2017，28（10）：2383-2385.
[13] Border WA，Ward HJ，Kamil ES，et al. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen [J]. J Clin Invest，1982，69（2）：451-461.
[14] 薛丕良，牛雯颖，李丽琦，等.雷公藤多苷联合小剂量激素治疗特发性膜性肾病的前瞻性对照研究[J].世界中医药，2019，14（3）：666-669.
[15] 赵亚云，方敬，陈静洁，等.三焦祛湿方对C-BSA诱导膜性肾病小鼠肾脏保护作用及其对Nrf2/HO-1信号通路的影响[J].中国实验方剂学杂志，2021，27（18）：58- 65.
[16] Ronco P，Debiec H. Pathophysiological advances in membranous nephropathy：time for a shift in patient’s care [J]. Lancet，2015，385（9981）：1983-1992.
[17] Motavalli R，Etemadi J，Kahroba，et al. Immune system- mediated cellular and molecular mechanisms in idiopathic membranous nephropathy pathogenesis and possible therapeutic targets [J]. Life Sci，2019，238：116923.
[18] Saleem MA，O’Hare MJ，Reiser J，et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression [J]. J Am Soc Nephrol，2002，13（3）：630-638.
[19] Akankwasa G，Jianhua L，Guixue C，et al. Urine markers of podocyte dysfunction：a review of podocalyxin and nephrin in selected glomerular diseases [J]. Biomark Med，2018，12（8）：927-935.
[20] 张欣欣，宋瑞婧，高飞，等.基于内质网应激GRP78/PERK/ CHOP信号通路探讨益肾通络方对膜性肾病大鼠足细胞凋亡的影响[J].中药药理与临床，2021，37（5）：102- 109.
[21] 高子涵，王红伟，吕行直，等.柴胡皂苷b2通过抑制线粒体凋亡通路减轻过氧化氢诱导的L-02细胞损伤[J].中国药理学与毒理学杂志，2018，32（7）：543-549.
[22] 程新燕，符翠莉.芹菜素对大鼠骨肉瘤细胞凋亡及相关蛋白Bax，Bcl-2，Caspase-3，Caspase-9，细胞色素C的影响[J].中国实验方剂学杂志，2016，22（15）：139- 142.
[23] Obeng E. Apoptosis（programmed cell death）and its signals-A review [J]. Braz J Biol，2021，81（4）：1133-1143.
[24] Lu H，Luo Y，Su B，et al. Wenyang Lishui Decoction Ameliorates Podocyte Injury in Membranous Nephropathy Rat and Cell Models by Regulating p53 and Bcl-2 [J]. EvidBased Complement Alternat Med，2020，2020：6813760.
京公网安备 11010502046598号